To understand the at-home ketamine boom, I spoke with 40+ patients. Many called the drug profoundly helpful, but some described addiction and bladder problems -- known risks of recreational use that have been largely downplayed in the medical community.
https://t.co/E4Nfr1NAZ7
Pandemic-era telemedicine rule changes have made it much easier to take the mind-altering drug ketamine at home. Many mental health patients have benefited, but the industry's rapid growth has outpaced evidence of safety. https://t.co/E4Nfr1NAZ7
Primed by glowing media coverage and aggressive advertising, many patients regard ketamine and its newfound at-home availability as akin to a miracle cure. But there are many unknowns -- and risks. An investigation by @ChrisDHamby@nytimes https://t.co/YqpDxExfbY
These workers are slowly suffocating to death after fabricating engineered-stone countertops: https://t.co/2f7BVlo1ZN
Great work by @JimGMorris @Multi_American @pubhealthwatch
Peruse for yourself the 100,00-plus documents that @PekingMike & I used to tell the story of McKinsey's broader work for opioid manufacturers: https://t.co/WTe9KTOA25
Our story: https://t.co/qnjUfEAvuf
In addition to helping Purdue Pharma "turbocharge" OxyContin sales while overdoses were surging in America, consulting giant McKinsey simultaneously worked with other drugmakers to boost $$$ of even stronger opioids like Opana.
@ChrisDHamby@PekingMike
https://t.co/ySNJRFMEaw
McKinsey's work for opioid makers went well beyond Purdue, a vast new trove of documents shows. The firm counseled companies at the core of the crisis.
w/@PekingMike https://t.co/qnjUfEAvuf
EXCLUSIVE: As part of its 2021 settlement with US states, McKinsey pledged to make public documents on its work with opioid makers going back more than a decade. The docs show the firm's advice extended well beyond Purdue Pharma. By @ChrisDHamby and me https://t.co/bSZc6y8sKS
Amid withering questioning from members of Congress, McKinsey's top executive maintained that simultaneously serving both Purdue Pharma and its chief regulator, the F.D.A., was not a conflict of interest. https://t.co/dEou3OBZ8n
In a hearing today, McKinsey's top executive apologized for the firm's work for opioid manufacturers. Members of Congress called his words hollow and referred to the $86 million McKinsey received from Purdue Pharma as "blood money."
w/@PekingMike@waltbogdanich
Op-ed from a retired miner with black lung: Benefits in jeopardy w/out action by Congress. "I am absolutely counting on Manchin to get this done." https://t.co/6UqhARkz7z
I had the privilege of speaking with Arvin for my book. His predicament hasn't dampened his jovial optimism.
Have a look at some of the documents we drew on to tell the story of McKinsey and its work for both opioid manufacturers and the F.D.A.:
https://t.co/CqSyiTh128
https://t.co/v0RKg2x52s
Newly released documents show: McKinsey consultants worked for both Purdue Pharma and its regulator, the F.D.A. The firm stressed its govt. connections when pitching pharma cos. -- "who we know and what we know." w/@waltbogdanich@PekingMike@jenvalentino https://t.co/KwraA4avI6
Overlooked No More: Elizabeth Hayes, the coal town doctor who fought for miners' health: https://t.co/jN7hwbM4k0
Appreciation to @greenhousenyt for telling the story.
For anyone looking for a good read on a timely subject, might I suggest my former @publicintegrity colleague Ronnie Greene's new book Heart of Atlanta: https://t.co/j65lqINpNe
It's the human story behind one of the most underappreciated Supreme Court civil rights cases.
Nice @niemanstory interview with @JimGMorris -- fellow @publicintegrity alumnus, legendary reporter and beard aficionado -- about launching a nonprofit investigative news outlet (@pubhealthwatch) during a pandemic: https://t.co/2suZ9mYfki
The @nytimesbooks list of 100 notable books is out, and Soul Full of Coal Dust made the cut! What a thrill to be among such great company. https://t.co/VZ5fOBcSrw
“It was pretty clear that we failed.” @ChrisDHamby and @SherylNYT reveal the backstory to the Covid vaccine production failures in Baltimore. A surprising cast of culprits. @nytimes https://t.co/1JRepTmktF